DKCM
PLRX icon

Davidson Kempner Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Davidson Kempner Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,000
Closed -$772K – 284
2020
Q2 		$772K Buy
+24,000
New +$637K 0.02% 169

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Davidson Kempner Capital Management's PLRX Position: Q3 2020 in Review

Davidson Kempner Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2020, closing a stake of 24,000 shares — an estimated $772K sold.

Davidson Kempner Capital Management first reported a position in PLRX in Q2 2020 and held it in 1 quarter. The position peaked at $772K in Q2 2020. 55 funds tracked by Wall St. Rank hold PLRX as of Q3 2020.

  • Davidson Kempner Capital Management reported no remaining Pliant Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 24,000 Pliant Therapeutics shares in Q3 2020, an estimated $772K.
  • Davidson Kempner Capital Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 1 quarter.
  • Davidson Kempner Capital Management's Pliant Therapeutics position peaked at $772K in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2020.

Based on Davidson Kempner Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.